Article Figures & Data
Figures
- FIGURE 1.
66-y-old woman with de novo metastatic, ER-positive lobular breast cancer. 18F-FES PET/CT shows more lesions than 18F-FDG PET/CT. ER tumor heterogeneity is also demonstrated with both 18F-FDG–negative, 18F-FES–positive lesions (white arrows) and 18F-FDG–positive, 18F-FES–negative lesions (red arrows).
Tables
Molecular subtype Proportion of breast cancer 4-y estimated survival HR-positive/HER2-negative 66.6% 92.5% HR-positive/HER2-positive 9.7% 90.3% HR-negative/HER2-positive 4.3% 82.7% Triple-negative 10.8% 77.0% HR = hormone receptor.
T stage N stage M stage Tx: primary not assessable Nx: not assessable M0: no distant metastases T0: no evidence of primary N0: no regional LN cM0(i+): tumor cells on circulating blood markers, marrow, or nonregional nodal tissue < 0.2 mm Tis: ductal carcinoma in situ N1: ipsilateral level I or II axillary LN M1: distant metastases T1: ≤20 mm N2: clinically fixed/matted ipsilateral level I or II axillary LN or clinically detected ipsilateral internal mammary LN T2: >20 but ≤50 mm N3: ipsilateral level III axillary LN, clinically detected ipsilateral internal mammary LN with level I or II axillary LN, or ipsilateral supraclavicular LN T3: >50 mm T4: any size with direct chest wall or skin extension T4d: IBC LN = lymph node.
Category Stage TNM description Early 1A T1N0M0 1B T0/T1, N1mi, M0 2A T0/or T1, N1, M0 T2, N0, M0 2B T2, N1, M0 Locally advanced 2B T3, N0, M0 3A T0/T1/T2, N2, M0 T3, N1/N2, M0 3B T4, N0, N1/N2, M0 3C Any T, N3, M0 Metastatic 4 Any T, Any N, M1
